Discussion about this post

User's avatar
Positively Paying It Forward's avatar

Dana,

Per your quote above:

"Homeopaths may not yet adequately understand precisely how their medicines work, but the body of historical and present-day evidence and experience is simply too significant to ignore. "

One could say/state the same about mRNA technology which has been deployed with reckless abandon upon the masses.

The difference between homeopathic medicines vs. mRNA medicines is stunningly clear, one heals/offers solutions and has successfully stood the test of time, while the other has a 'spotty' (I'm being nice) record at best.

PS:

I see you posting over at Dr. Vinay Prasad's recent measles article, "Public health's stupidity will lead to more…".

You mention benefits of (your comment):

"childhood diseases provide important cardiovascular and immunological benefits"

I tried posting but I'm not a paid suscriber.

Worth mentioning the 'oncological' benefits as well of measles.

https://pmc.ncbi.nlm.nih.gov/articles/PMC5086626/

Measles to the Rescue: A Review of Oncolytic Measles Virus

Abstract

Oncolytic virotherapeutic agents are likely to become serious contenders in cancer treatment. The vaccine strain of measles virus is an agent with an impressive range of oncolytic activity in pre-clinical trials with increasing evidence of safety and efficacy in early clinical trials. This paramyxovirus vaccine has a proven safety record and is amenable to careful genetic modification in the laboratory. Overexpression of the measles virus (MV) receptor CD46 in many tumour cells may direct the virus to preferentially enter transformed cells and there is increasing awareness of the importance of nectin-4 and signaling lymphocytic activation molecule (SLAM) in oncolysis. Successful attempts to retarget MV by inserting genes for tumour-specific ligands to antigens such as carcinoembryonic antigen (CEA), CD20, CD38, and by engineering the virus to express synthetic microRNA targeting sequences, and “blinding” the virus to the natural viral receptors are exciting measures to increase viral specificity and enhance the oncolytic effect. Sodium iodine symporter (NIS) can also be expressed by MV, which enables in vivo tracking of MV infection. Radiovirotherapy using MV-NIS, chemo-virotherapy to convert prodrugs to their toxic metabolites, and immune-virotherapy including incorporating antibodies against immune checkpoint inhibitors can also increase the oncolytic potential. Anti-viral host immune responses are a recognized barrier to the success of MV, and approaches such as transporting MV to the tumour sites by carrier cells, are showing promise. MV Clinical trials are producing encouraging preliminary results in ovarian cancer, myeloma and cutaneous non-Hodgkin lymphoma, and the outcome of currently open trials in glioblastoma multiforme, mesothelioma and squamous cell carcinoma are eagerly anticipated.

I'll keep reading your work and thank you for all you're doing to put sunlight on the disease of Pharma.

Best

Greg

Expand full comment
JustANobody's avatar

Thank you for making this simple to understand.

Expand full comment
8 more comments...

No posts